Seretra
✅ Reduces airway inflammation
✅ Improves lung function
✅ Relieves asthma symptoms
✅ Prevents bronchoconstriction
✅ Enhances respiratory health
Seretra contains Seratrodast.
✓ Medicinsk gennemgået af Morgan Ellis — Apoteksforsker · 8 års erfaring · Sidst gennemgået: maj 2026
⚡ Quick Answer — What is Seretra?
Seretra indeholder seratrodast 80 mg, en selective thromboxane A2 (TXA2) receptor antagonist used as preventer therapy for asthma and allergic rhinitis. Seratrodast blocks the TXA2 receptor on bronchial smooth muscle, eosinophils, and platelets — preventing TXA2-mediated bronchoconstriction, eosinophil recruitment, and airway hyperresponsiveness. It was developed and is mainly used in Japan; less widely available outside Asia. Used as add-on preventer alongside ICS in patients with persistent asthma. Onset of preventer benefit takes 1–2 weeks of daily dosing.
📦 Hver ordre er dækket af vores Reshipment Assurance Policy — hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.
Hvorfor bestille fra MedsBase
Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomspændende i diskret, neutral emballage — ingen medicinnavn på pakkens ydre. Kortbetalinger håndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor — aldrig “MedsBase” eller medicinnavn). Crypto og SEPA bankoverførsel accepteres også. Hver ordre er dækket af vores Reshipment Assurance Policy.
What Is Seretra?
Seretra contains seratrodast — a niche anti-asthma agent introduced in Japan in 1995. Seratrodast targets the thromboxane A2 (TXA2) receptor — a contrast to leukotriene receptor antagonists (montelukast) which target the cysteinyl leukotriene receptor. Both TXA2 and leukotrienes are inflammatory mediators released during the allergic cascade.
How Does Seratrodast Work?
- TXA2 receptor blockade on bronchial smooth muscle prevents TXA2-mediated bronchoconstriction
- Reduces eosinophil recruitment to airways
- Decreases airway hyperresponsiveness over 1–2 weeks of dosing
- Mild platelet inhibition — TXA2 is a potent platelet aggregator; this effect is rarely clinically significant
— det forstærker den normale fysiologiske respons snarere end at udløse en kunstigt.
- Persistent asthma — add-on preventer when ICS alone is inadequate
- Allergic rhinitis — adjunct
- Cough-variant asthma
- Aspirin-exacerbated respiratory disease (AERD) — niche use
Seretra Dosage
| Patient | Dosis | Hyppighed |
|---|---|---|
| Adults | 80 mg | Once daily after dinner |
| Hepatic impairment | Reduce dose 50% | Once daily |
Side Effects of Seretra
- Nausea, dyspepsia
- Hovedpine
- Mild dizziness
- Mild liver enzyme elevation
- Rarely: rash, fatigue
Serious — stop and seek help:
- Hepatitis (jaundice, dark urine, RUQ pain)
- Severe allergic reaction
- Severe persistent vomiting
Advarsler og forholdsregler
- Liver function monitoring: baseline LFTs and periodic monitoring during long-term use.
- Continue ICS if previously prescribed; seratrodast is add-on, not replacement.
- Not a rescue medication. Use SABA (Asthalin, Levolin) for acute attacks.
- Graviditet og amning: limited data; avoid unless benefit clear.
- Bleeding disorders: mild TXA2 inhibition could theoretically prolong bleeding; rarely clinically significant.
Kontraindikationer
- Hypersensitivity to seratrodast
- Severe hepatic impairment
- Active hepatitis
Lægemiddelinteraktioner
- Aspirin and other antiplatelet agents — additive bleeding risk (rarely clinically significant)
- Warfarin — monitor INR
- Other hepatotoxic drugs — monitor LFTs
Opbevaring
- Store below 25°C in a cool, dry place away from direct sunlight.
- Keep in original packaging until use to protect from moisture and light.
- Do not use after the expiry date printed on the strip.
- Keep out of reach of children.
Relaterede alternativer på MedsBase
- Asthalin Inhaler — salbutamol reliever
- Budecort Inhaler — budesonide ICS preventer
- Foracort Inhaler — budesonide + formoterol ICS-LABA
- Montair — montelukast LTRA tablet
- Tiova Inhaler — tiotropium LAMA for COPD
Ofte stillede spørgsmål
How is seratrodast different from montelukast?
Both block specific allergic mediators. Montelukast (Montair) blocks the cysteinyl leukotriene CysLT1 receptor. Seratrodast blocks the thromboxane A2 receptor. Different mediators, different targets, similar add-on niche. Montelukast has more global use and a stronger evidence base; seratrodast is mainly used in Japan and parts of Asia.
Can I take Seretra alongside montelukast?
Combination is not standard. Discuss with your prescriber — there is no established additional benefit over ICS-LABA + LTRA.
How long until Seretra works?
1–2 weeks for noticeable improvement; 4–8 weeks for full preventer effect on exacerbation rate.
Is Seretra a rescue inhaler?
No — onset is far too slow. Use a SABA (Asthalin, Levolin) for acute attacks.
Why monitor liver function?
Mild liver enzyme elevation is a known side effect. Baseline LFTs and periodic monitoring are recommended.
Will Seretra replace my inhaler?
No — seratrodast is an oral add-on. Continue ICS or ICS-LABA inhaler therapy.
Is Seretra evidence-based?
Yes, but mainly through Japanese trials. Evidence base is smaller than for montelukast or ICS-LABA combinations. Reasonable as add-on in selected patients.
Can children take Seretra?
Limited paediatric data; specialist supervision required.
Is Seretra safe in pregnancy?
Limited data; avoid unless benefit clear.
Relaterede alternativer
Andre produkter inden for Kroniske tilstande som kunder også ser:
More options in Asthma/COPD Treatment
Rangeret efter seneste MedsBase ordrevolumen — hvad andre kunder i denne kategori vælger.
| Styrke | 80 mg |
|---|---|
| Antal | 30 Tablet/s, 60 Tablet/s, 90 Tablet/s, 180 Tablet/s |
Seretra
Spørgsmål & svar
Seretra
Relaterede produkter
Anmeldelser
Der er ingen anmeldelser endnu